Alector, INC 10-Q quarterly reports

Alector, Inc. reported a significant net loss in Q3 2025, discontinued its Phase 3 latozinemab trial, and announced further workforce reductions to realign strategic priorities.

Alector, a late-stage clinical biotechnology company, reported a reduced net loss in Q2 2025, extended its cash runway into H2 2027, and provided updates on its neurodegeneration pipeline, including Phase 3 and Phase 2 trials.

Alector, Inc. announces its Q1 2025 financial results, highlighting progress in clinical trials and strategic pipeline advancements despite a net loss of $40.5 million.

Alector Inc. released its 10-Q filing for the quarter ended September 30, 2024, detailing financial results and providing updates on its clinical programs.

Alector Inc. released its 10-Q filing for the quarter ended June 30, 2024, detailing financial results and providing updates on its clinical programs.

Alector Inc. announced its first quarter 2024 financial results, highlighting progress in clinical trials and a recent public offering.